---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004046"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:50:27.949809+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian reports positive Phase 1/2 data for VRDN-001 in thyroid eye disease; 71% proptosis responders across doses

## Summary
- 3 mg/kg cohort: 67% proptosis responders, 56% overall responders, 67% achieved CAS 0/1, 20% complete diplopia resolution at week 6.
- Across all 21 drug-treated patients: 71% proptosis responders, 67% overall responders, 62% CAS 0/1, 54% complete diplopia resolution.
- No serious adverse events, discontinuations, or infusion reactions reported with VRDN-001 across dose levels.
- Low-dose data support once-monthly subcutaneous dosing profile for VRDN-002 and VRDN-003; VRDN-003 IND planned Q2 2023.
- Phase 3 THRIVE trial enrollment ongoing; results expected mid-2024; chronic TED proof-of-concept data expected H1 2023.

## SEC filing metadata
- accession: 0001193125-23-004046
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/0001193125-23-004046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312523004046/d427009d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004046
- JSON: https://secwatch.observer/filing/0001193125-23-004046.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004046.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.